AU2017231832B2 - CXCR-2 inhibitors for treating crystal arthropathy disorders - Google Patents

CXCR-2 inhibitors for treating crystal arthropathy disorders Download PDF

Info

Publication number
AU2017231832B2
AU2017231832B2 AU2017231832A AU2017231832A AU2017231832B2 AU 2017231832 B2 AU2017231832 B2 AU 2017231832B2 AU 2017231832 A AU2017231832 A AU 2017231832A AU 2017231832 A AU2017231832 A AU 2017231832A AU 2017231832 B2 AU2017231832 B2 AU 2017231832B2
Authority
AU
Australia
Prior art keywords
colchicine
compound
inhibitor
cxcr
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017231832A
Other languages
English (en)
Other versions
AU2017231832A1 (en
Inventor
Jeffrey Miner
Payal Nanavati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of AU2017231832A1 publication Critical patent/AU2017231832A1/en
Application granted granted Critical
Publication of AU2017231832B2 publication Critical patent/AU2017231832B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017231832A 2016-03-11 2017-03-09 CXCR-2 inhibitors for treating crystal arthropathy disorders Ceased AU2017231832B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307348P 2016-03-11 2016-03-11
US62/307,348 2016-03-11
PCT/US2017/021570 WO2017156270A1 (en) 2016-03-11 2017-03-09 Cxcr-2 inhibitors for treating crystal arthropathy disorders

Publications (2)

Publication Number Publication Date
AU2017231832A1 AU2017231832A1 (en) 2018-10-04
AU2017231832B2 true AU2017231832B2 (en) 2021-11-11

Family

ID=59789863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017231832A Ceased AU2017231832B2 (en) 2016-03-11 2017-03-09 CXCR-2 inhibitors for treating crystal arthropathy disorders

Country Status (10)

Country Link
US (1) US10772886B2 (OSRAM)
EP (1) EP3426253A4 (OSRAM)
JP (2) JP6883917B2 (OSRAM)
CN (2) CN109152780B (OSRAM)
AU (1) AU2017231832B2 (OSRAM)
BR (1) BR112018068393A2 (OSRAM)
CA (1) CA3017345A1 (OSRAM)
CO (1) CO2018010880A2 (OSRAM)
MX (1) MX386771B (OSRAM)
WO (1) WO2017156270A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
EP3681861A4 (en) * 2017-09-12 2021-06-09 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF DISORDERS
CN111727184B (zh) 2018-01-11 2022-06-28 深圳嘉科生物科技有限公司 Cxcr2拮抗剂
US12577235B2 (en) 2019-07-11 2026-03-17 Shenzhen Optimum Biological Technology Co., Ltd Crystalline form of CXCR2 antagonist and application thereof
KR102260478B1 (ko) * 2019-08-19 2021-06-02 연세대학교 산학협력단 일나트륨 요소화물 결정 용해용 조성물
TW202210068A (zh) * 2020-06-05 2022-03-16 美商雅力思提雅治療公司 用於治療家族性地中海型發熱病的cxcr-2抑制劑
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124619A1 (en) * 2004-08-28 2011-05-26 David Ranulf Cheshire Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
WO2013008002A1 (en) * 2011-07-12 2013-01-17 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
US20140256678A1 (en) * 2010-08-23 2014-09-11 Syntrix Biosystems, Inc. Aminopyrimidinecarboxamides as CXCR2 Modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CA2554709C (en) 2004-01-30 2011-11-15 Schering Corporation Crystalline polymorphs of a cxc-chemokine receptor ligand
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2203432A4 (en) 2007-09-21 2011-04-27 Glaxosmithkline Llc PROCESSING METHOD
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
WO2009117710A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation
CA2730477A1 (en) 2008-07-16 2010-01-21 Astrazeneca Ab Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
MX2011003328A (es) 2008-10-06 2011-06-20 Carolus Therapeutics Inc Metodos para tratar inflamacion.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
WO2011038149A2 (en) 2009-09-23 2011-03-31 Carolus Therapeutics, Inc. Methods of treating inflammation
WO2011116245A2 (en) 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
WO2012007748A1 (en) * 2010-07-13 2012-01-19 Astrazeneca Ab New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
US20180221312A1 (en) 2016-03-11 2018-08-09 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating disorders
EP3681861A4 (en) 2017-09-12 2021-06-09 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124619A1 (en) * 2004-08-28 2011-05-26 David Ranulf Cheshire Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
US20140256678A1 (en) * 2010-08-23 2014-09-11 Syntrix Biosystems, Inc. Aminopyrimidinecarboxamides as CXCR2 Modulators
WO2013008002A1 (en) * 2011-07-12 2013-01-17 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
US20140228339A1 (en) * 2011-07-12 2014-08-14 Astrazeneca Ab Novel Compound

Also Published As

Publication number Publication date
US10772886B2 (en) 2020-09-15
CA3017345A1 (en) 2017-09-14
CN109152780B (zh) 2021-10-01
CO2018010880A2 (es) 2018-10-22
EP3426253A4 (en) 2019-11-06
BR112018068393A2 (pt) 2019-01-15
AU2017231832A1 (en) 2018-10-04
CN113893252A (zh) 2022-01-07
US20180235964A1 (en) 2018-08-23
MX2018010946A (es) 2019-05-23
JP2019507791A (ja) 2019-03-22
CN109152780A (zh) 2019-01-04
JP6883917B2 (ja) 2021-06-09
EP3426253A1 (en) 2019-01-16
MX386771B (es) 2025-03-19
WO2017156270A1 (en) 2017-09-14
JP7126014B2 (ja) 2022-08-25
JP2021121600A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
JP7126014B2 (ja) 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤
EP1465638B1 (en) Phosphate transport inhibitors
TW201919599A (zh) 用於治療病症之cxcr-2抑制劑
JP6434416B2 (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
US20200281878A1 (en) Cxcr-2 inhibitors for treating disorders
WO2022261777A1 (en) Use of atr inhibitors in combination with parp inhibitors for treating cancer
EA027654B1 (ru) Комбинация панобиностата и руксолитиниба при лечении рака, такого как миелопролиферативное новообразование
TW202502325A (zh) 治療黑色素瘤的藥物組合的用途
RS63534B1 (sr) Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu upotrebu
US20240122927A1 (en) Methods for treating hemolytic diseases and sickle cell disease
US20250235426A1 (en) Pharmaceutical Combination and Use Thereof
KR20220059519A (ko) 키나제 억제제에 의한 한선염의 치료
JP6879557B2 (ja) インフラマソームを標的とする低分子化合物
US20140127295A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
HK40058722A (en) Cxcr-2 inhibitors for treating crystal arthropathy disorders
RS58382B1 (sr) Hidrobromidna so n-{4-hloro-2-hidroksi-3-[(3s)-3-piperidinilsulfonil]fenil}-n’-(3-fluoro-2-metilfenil)uree
US11351172B2 (en) Pharmaceutical composition and use for applying ribociclib in phosphodiesterase 4-mediated disease treatment of patient and inhibition of phosphodiesterase 4 activity
WO2025181153A1 (en) Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025229051A1 (en) Use of atr inhibitors in combination with antiandrogen agent
WO2026081738A1 (zh) PI3Kα突变选择性抑制剂的用途
US8791110B2 (en) Anti-arenaviral compounds
IL298748A (en) Use of a combination of colchicine and a CXCR-2 inhibitor for the treatment or prevention of hereditary Mediterranean fever (FMF) and its outbreaks
TOTHENIC et al. Calcium hydrogen phosphate. Source

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired